

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	7
1. Background.....	9
2. Objective and Scope	9
3. Selection of Topics for Monographs	10
4. Data for Monographs	11
5. The Working Group	11
6. Working Procedures	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	20
11. Summary of Data Reported	22
12. Evaluation	23
13. References.....	28
GENERAL REMARKS.....	33
THE MONOGRAPHS.....	37
Betel-quid and Areca-nut Chewing	39
1. Exposure Data.....	41
1.1 Composition of betel quid.....	41
1.1.1 Betel quid	41
1.1.2 Areca nut.....	42
1.1.3 Betel leaf.....	50
1.1.4 Betel inflorescence	50
1.1.5 Slaked lime	50
1.1.6 Catechu	51
1.1.7 Tobacco	51
1.1.8 Miscellaneous additives and contaminants.....	51
1.2 Areca nut-based industrial packaged products	52
1.3 Consumption by geographical region	52

1.3.1	India	52
	(a) Adults	53
	(b) Children and adolescents	59
1.3.2	Pakistan	61
1.3.3	Bangladesh	62
1.3.4	Sri Lanka	62
1.3.5	Maldives	63
1.3.6	People's Republic of China	63
1.3.7	Taiwan, China	64
1.3.8	Myanmar	68
1.3.9	Thailand	68
1.3.10	Lao People's Democratic Republic	69
1.3.11	Cambodia	69
1.3.12	Malaysia	69
1.3.13	Singapore	70
1.3.14	Indonesia	70
1.3.15	The Philippines	71
1.3.16	Papua New Guinea	71
1.3.17	Palau	72
1.3.18	Guam	73
1.3.19	Others	73
1.3.20	Migrant populations	74
	(a) South Africa	74
	(b) United Kingdom	75
	(c) Others	78
1.3.21	Placement of the quid in the mouth	78
1.4	Regulations and legislation	78
	Regulation of import and sale of areca-containing products	79
	(a) India	79
	(b) North America	79
	(c) European Union	79
	(d) Limited bans in other countries	80
2.	Studies of Cancer in Humans	80
2.1	Oral cancer	80
2.1.1	India, Pakistan and Sri Lanka	80
	(a) Descriptive studies and case series	80
	(b) Cohort studies	86
	(c) Case-control studies	87
	(d) Cross-sectional surveys	101
	(e) Synergism	101
2.1.2	Taiwan, China	104
	(a) Descriptive study	104

	(b) Case-control studies	105
2.1.3	South-East Asia	108
	(a) Malaysia	108
	(b) Myanmar	110
	(c) Thailand	110
2.1.4	Papua New Guinea	111
2.1.5	Migrant populations	112
	(a) South Africa	112
	(b) United Kingdom.....	112
2.2	Some betel quid-associated lesions, and precancerous lesions and conditions	113
2.2.1	Introduction.....	113
2.2.2	Betel quid-associated oral lesions.....	113
2.2.3	Leukoplakia and erythroplakia	113
	(a) India	114
	(b) Taiwan, China	116
	(c) South-East Asia	123
	(d) Migrants	123
2.2.4	Oral submucous fibrosis	123
	(a) India and Pakistan	123
	(b) People's Republic of China	127
	(c) Taiwan, China	128
	(d) South-East Asia	128
	(e) Migrants	128
2.2.5	Oral lichen planus	129
	(a) India	129
	(b) South-East Asia	130
2.2.6	Multiple and mixed lesions.....	130
2.2.7	Malignant transformation	131
	(a) India and Pakistan	131
	(b) Taiwan, China	132
	(c) Migrants	132
2.3	Other upper aerodigestive cancer	132
2.3.1	India	132
2.3.2	Taiwan, China	137
2.4	Other cancers.....	137
2.4.1	Stomach cancer	137
2.4.2	Lung cancer.....	137
2.4.3	Cervical cancer	139
2.4.4	Liver cancer	139
	(a) Taiwan, China	139
	(b) Thailand	140

3. Studies of Cancer in Experimental Animals.....	142
3.1 Oral administration	142
3.1.1 Mouse	142
3.1.2 Rat	145
3.1.3 Hamster.....	146
3.2 Skin application.....	147
Mouse	147
3.3 Subcutaneous administration	147
3.3.1 Mouse	147
3.3.2 Rat.....	148
3.4 Intraperitoneal administration.....	148
Mouse	148
3.5 Administration to the oral mucosa or cheek pouch	149
3.5.1 Rat.....	149
3.5.2 Hamster.....	149
3.5.3 Baboon	154
3.6 Intravaginal instillation	154
Mouse	154
3.7 Administration with known carcinogens or modifiers of cancer risk ..	154
3.7.1 Mouse	154
3.7.2 Rat	156
3.7.3 Hamster.....	156
4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	160
4.1 Absorption, distribution, metabolism and excretion.....	160
4.1.1 Humans	160
(a) Constituents of betel quid	160
(b) Biomarkers of constituents of betel quid.....	162
4.1.2 Experimental systems	166
(a) Areca nut/arecoline	166
(b) Betel leaf/hydroxychavicol/eugenol	168
(c) Formation of nitrosamines	169
(d) Formation of reactive oxygen species from betel-quid ingredients	170
(e) Antioxidant effects.....	172
4.2 Physiological and toxic effects	173
4.2.1 Humans	173
(a) Psychopharmacological effects	173
(b) Effects on oral hard and soft tissues	173
(c) Effects on various physiological systems	175
(d) Other effects.....	180

4.2.2	Experimental systems	180
	(a) In-vivo studies	180
	(b) In-vitro studies	186
4.3	Reproductive and developmental effects	190
4.3.1	Humans	190
4.3.2	Experimental systems	191
	(a) <i>Pan masala</i>	191
	(b) Areca nut	192
	(c) Arecoline	192
	(d) Stems of <i>Piper betle</i>	193
	(e) Nicotine	193
4.4	Genetic and related effects	194
4.4.1	Humans	194
	(a) Genotoxicity and mutagenicity	194
	(b) Genomic instability	196
	(c) Oncogenes and tumour-suppressor genes	196
	(d) Polymorphism in carcinogen-metabolizing enzymes	203
4.4.2	Experimental systems	213
	(a) Genotoxicity and mutagenicity	213
	(b) Oncogenes and tumour-suppressor genes	226
	(c) Polymorphisms in carcinogen metabolizing genes	227
	(d) Markers of tumour promotion	227
	(e) Preventive effects	227
4.5	Mechanistic considerations	228
5.	Summary of Data Reported and Evaluation	230
5.1	Exposure data	230
5.2	Human carcinogenicity data	231
5.3	Animal carcinogenicity data	232
5.4	Other relevant data	235
5.5	Evaluation	238
6.	References	239
Some Areca-nut-derived N-Nitrosamines		279
1.	Exposure Data	281
1.1	Chemical and physical data	281
	1.1.1 Synonyms and structural and molecular formulae	281
	1.1.2 Chemical and physical properties	282
1.2	Production	282
1.3	Occurrence	283
1.4	Analysis	284
2.	Studies of Cancer in Humans	284

3. Studies of Cancer in Experimental Animals.....	284
3.1 3-Methylnitrosaminopropionaldehyde	284
3.2 3-Methylnitrosaminopropionitrile.....	284
3.2.1 Oral application.....	284
3.2.2 Subcutaneous administration	285
3.2.3 Administration with known carcinogens or modifiers of cancer risk.....	285
3.3 <i>N</i> -Nitrosoguvacoline	286
3.3.1 Oral administration	286
3.3.2 Administration with known carcinogens or modifiers of cancer risk.....	286
4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	287
4.1 Absorption, distribution, metabolism and excretion.....	287
4.1.1 Humans	287
4.1.2 Experimental systems	287
4.2 Toxic effects	287
4.2.1 Humans	287
4.2.2 Experimental systems	287
4.3 Reproductive and developmental effects	288
4.4 Genetic and related effects	288
4.4.1 Humans	288
4.4.2 Experimental systems	288
5. Summary of Data Reported and Evaluation.....	291
5.1 Exposure data	291
5.2 Human carcinogenicity data	291
5.3 Animal carcinogenicity data	291
5.4 Other relevant data	292
5.5 Evaluation	292
6. References.....	293
 GLOSSARY A	 295
 GLOSSARY B	 297
 CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES.....	 301

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.